About Aclaris Therapeutics
Aclaris Therapeutics is a company based in Malvern (United States) founded in 2012 by Frank Ruffo and Neal Walker.. Aclaris Therapeutics has raised $82 million across 10 funding rounds from investors including HHS, RA Capital and STRS Ohio. The company has 64 employees as of December 31, 2024. Aclaris Therapeutics has completed 1 acquisition, including Confluence Life Sciences. Aclaris Therapeutics offers products and services including ATI-052 and Drug Development Pipeline. Aclaris Therapeutics operates in a competitive market with competitors including Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences, Septerna and Upstream Bio, among others.
- Headquarter Malvern, United States
- Employees 64 as on 31 Dec, 2024
- Founders Frank Ruffo, Neal Walker
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aclaris Therapeutics, Inc.
-
Annual Revenue
$18.72 M-40.09as on Dec 31, 2024
-
Net Profit
$-132.06 M-49.26as on Dec 31, 2024
-
EBITDA
$-49.02 M56.87as on Dec 31, 2024
-
Total Equity Funding
$82 M (USD)
in 10 rounds
-
Latest Funding Round
$80 M (USD), Post-IPO
Nov 19, 2024
-
Investors
HHS
& 10 more
-
Employee Count
64
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Aclaris Therapeutics
Aclaris Therapeutics is a publicly listed company on the NASDAQ with ticker symbol ACRS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Aclaris Therapeutics
Aclaris Therapeutics offers a comprehensive portfolio of products and services, including ATI-052 and Drug Development Pipeline. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Bispecific antibody targeting TSLP and IL-4R for immuno-inflammatory treatments.
System for advancing investigational candidates in clinical trials.
Unlock access to complete
Unlock access to complete
Funding Insights of Aclaris Therapeutics
Aclaris Therapeutics has successfully raised a total of $82M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $80 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Post-IPO — $80.0M
-
First Round
First Round
(30 Aug 2012)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2024 | Amount | Post-IPO - Aclaris Therapeutics | Valuation |
investors |
|
| Apr, 2020 | Amount | Post-IPO - Aclaris Therapeutics | Valuation |
investors |
|
| Aug, 2018 | Amount | Post-IPO - Aclaris Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aclaris Therapeutics
Aclaris Therapeutics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, RA Capital and STRS Ohio. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in the US
|
Founded Year | Domain | Location | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location | |
|
A healthcare-focused investment firm supporting innovative company growth.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aclaris Therapeutics
Aclaris Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Confluence Life Sciences. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Kinase inhibitors are developed for cancer and autoimmune diseases.
|
2010 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Aclaris Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aclaris Therapeutics Comparisons
Competitors of Aclaris Therapeutics
Aclaris Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences, Septerna and Upstream Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for allergic and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aclaris Therapeutics
Frequently Asked Questions about Aclaris Therapeutics
When was Aclaris Therapeutics founded?
Aclaris Therapeutics was founded in 2012.
Where is Aclaris Therapeutics located?
Aclaris Therapeutics is headquartered in Malvern, United States. It is registered at Malvern, Pennsylvania, United States.
Who is the current CEO of Aclaris Therapeutics?
Neal Walker is the current CEO of Aclaris Therapeutics. They have also founded this company.
Is Aclaris Therapeutics a funded company?
Aclaris Therapeutics is a funded company, having raised a total of $82M across 10 funding rounds to date. The company's 1st funding round was a Post-IPO of $10M, raised on Aug 30, 2012.
How many employees does Aclaris Therapeutics have?
As of Dec 31, 2024, the latest employee count at Aclaris Therapeutics is 64.
What is the annual revenue of Aclaris Therapeutics?
Annual revenue of Aclaris Therapeutics is $18.72M as on Dec 31, 2024.
What does Aclaris Therapeutics do?
Aclaris Therapeutics focused on the development of novel dermatologic therapies. Its lead product, A-101 is a proprietary high-concentration hydrogen peroxide topical solution being developed for the treatment of seborrheic keratosis (Phase 3). The company also is pursuing additional dermatological indications for A-101, such as the treatment of common warts (Phase 2). In Sep 2015, Aclaris acquired a portfolio of oral and topical Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata and other dermatological conditions (preclinical).
Who are the top competitors of Aclaris Therapeutics?
Aclaris Therapeutics's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
What products or services does Aclaris Therapeutics offer?
Aclaris Therapeutics offers ATI-052 and Drug Development Pipeline.
Is Aclaris Therapeutics publicly traded?
Yes, Aclaris Therapeutics is publicly traded on NASDAQ under the ticker symbol ACRS.
How many acquisitions has Aclaris Therapeutics made?
Aclaris Therapeutics has made 1 acquisition, including Confluence Life Sciences.
Who are Aclaris Therapeutics's investors?
Aclaris Therapeutics has 11 investors. Key investors include HHS, RA Capital, STRS Ohio, Aisling Capital, and Rock Springs Capital.
What is Aclaris Therapeutics's ticker symbol?
The ticker symbol of Aclaris Therapeutics is ACRS on NASDAQ.